Cost-effectiveness of two antiviral therapies for chronic hepatitis B in Peru: entecavir and tenofovir

Authors

  • Rafael Bolaños-Díaz Unidad de Análisis y Generación de Evidencias en Salud Pública. Centro Nacional de Salud Pública. Instituto Nacional de Salud. Lima, Perú. Organización Médica para el desarrollo de la Salud. Lima, Perú. Médico cirujano; magíster en Epidemiología clínica; magíster en Economía de la Salud
  • Romina A. Tejada Unidad de Análisis y Generación de Evidencias en Salud Pública. Centro Nacional de Salud Pública. Instituto Nacional de Salud. Lima, Perú. Médico cirujano; magíster en Epidemiología clínica http://orcid.org/0000-0003-4420-5289
  • César Sanabria Unidad de Posgrado de Economía. Universidad Nacional Mayor de San Marcos. Lima, Perú. economista
  • Seimer Escobedo-Palza Sociedad Peruana de Administración de Salud. Lima, Perú. Médico cirujano

DOI:

https://doi.org/10.17843/rpmesp.2017.343.2496

Keywords:

Hepatitis B, Anti-Retroviral Agents, Economics, Medical

Abstract

Objetives. To compare in terms of cost-effectiveness to entecavir (ETV) and tenofovir (TDF) in the treatment of hepatitis B virus (HBV) in public hospitals in Peru. Materials and methods. We structured a Markov model. We define effectiveness adjusted life years for quality (QALY). We include the direct costs of treatment in soles from the perspective of the Ministry of Health of Peru. We estimate the relationship between cost and effectiveness ratios (ICER). We performed sensitivity analyzes considering a range of willingness to pay (WTP) from one to three times the Gross Domestic Product (GDP) per capita, and a tornado analysis regarding Monetary Net Profit (BMN) or ICER. Results. Treatment with TDF is more effective and less expensive than ETV. The ETV had a cost per QALY of PEN 4482, and PEN 1526 TDF. The PTO maintains a progressively larger with increasing WTP BMN. The discount rate was the only variable with a significant effect on model uncertainty. Conclusion: Treatment with TDF is more cost-effective than ETV in public hospitals in Peru.

Downloads

Download data is not yet available.

Published

2017-09-29

Issue

Section

Original Article

How to Cite

1.
Bolaños-Díaz R, Tejada RA, Sanabria C, Escobedo-Palza S. Cost-effectiveness of two antiviral therapies for chronic hepatitis B in Peru: entecavir and tenofovir. Rev Peru Med Exp Salud Publica [Internet]. 2017 Sep. 29 [cited 2024 Oct. 15];34(3):377-85. Available from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/2496

Most read articles by the same author(s)